Company description
Hikma is a multinational pharmaceutical company. Listed on the London Stock Exchange, we are a global company with a local presence across North America, MENA and Europe, providing our customers with a broad range of generic, specialty and branded pharmaceutical products.

Acting responsibly
At Hikma, we strive to put better health, within reach, every day and make a difference to people’s lives. We have a duty to act responsibly: for our people, patients, communities and the planet. We have identified four focus areas where we can drive positive impact.

Injectables
We supply hospitals across our markets with generic injectables, supported by our manufacturing facilities in the US, Europe and MENA.

Branded
We supply branded generics and in-licensed patented products from our local manufacturing facilities to retail and hospital customers across the MENA region.

Generics
We supply oral and other non-injectable generic and specialty branded products in the US retail market, leveraging our state-of-art manufacturing facility in Columbus, Ohio.

Key group financials (Year end December 2022)

<table>
<thead>
<tr>
<th>Core revenue</th>
<th>2022: $2,517m</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2021: $2,553m</td>
</tr>
<tr>
<td>Core operating profit</td>
<td>2022: $596m</td>
</tr>
<tr>
<td></td>
<td>2021: $632m</td>
</tr>
<tr>
<td>Core EBITDA</td>
<td>2022: $694m</td>
</tr>
<tr>
<td></td>
<td>2021: $727m</td>
</tr>
<tr>
<td>Core basic EPS</td>
<td>2022: 181.3c</td>
</tr>
<tr>
<td></td>
<td>2021: 194.8c</td>
</tr>
<tr>
<td>DPS</td>
<td>2022: 56c</td>
</tr>
<tr>
<td></td>
<td>2021: 54c</td>
</tr>
<tr>
<td>Net debt to EBITDA</td>
<td>2022: 1.5x</td>
</tr>
<tr>
<td></td>
<td>2021: 0.6x</td>
</tr>
</tbody>
</table>

Core results show the underlying performance of the Group, excluding exceptional items.

Company strengths

- Unique and diversified business model
- Strong market position
- Commitment to quality
- Large and growing portfolio and pipeline
- Return on invested capital

Company description
Hikma's strategy is to deliver high quality, affordable medicines and make healthcare more accessible to patients by delivering more from its strong foundation, inspiring and enabling its people, and building a portfolio that anticipates future health needs across its three business segments.

Injectables
- Generic injectable manufacturer in the US
- Pharmaceutical company in MENA

Branded
- #3 generic injectable manufacturer in the US
- #3 pharmaceutical company in MENA

Generics
- 13 US FDA inspected plants
- 12 EMA-inspected plants
- 760+ Products
- 200+ Projects in our pipeline

% Group core revenue

- US 57% (2021: 59%)
- MENA 34% (2021: 33%)
- Europe & ROW 9% (2021: 8%)

1. Source: IQVIA MAT through December 2022, generic injectable volumes by eaches, excluding branded generics and Becton Dickinson
2. Source: IQVIA MIDAS® World Review Pack Premium Monthly based on Values (USD MNF) for the period MAT September 2022 reflecting estimates of real-world activity in the following countries: ALGERIA, EGYPT, JORDAN, KUWAIT, LEBANON, MOROCCO, SAUDI ARABIA, TUNISIA, UAE

© Hikma Pharmaceuticals PLC 2023
Injectables

Core Revenue

$1,141m

- US 67%
- Europe/ROW 18%
- MENA 16%

Core Op. Profit

$428m

38% margin

Key focus areas

- Continue to grow our base business through our scale and strength of customer relationships
- Launch between 10 to 15 products in the US every year
- Strengthen MENA and expand EU

Products: Includes anti-infectives, pain management, cardiovascular, oncology, compounded sterile injectables

Customers: Includes hospitals, Group Purchasing Organisations, Civica Rx

Capabilities: Includes sterile liquid, powder, lyophilised and cytotoxic products, in a broad range of forms, including vials, ampules, bags and prefilled syringes, manufactured in facilities in the US, Portugal, Germany, Italy and MENA

Branded

Core Revenue

$691m

Key focus areas

- We operate in 18 markets across the MENA region, with a tiered approach, focusing on the highest value markets (Tier 1: Saudi Arabia, Algeria, Egypt)
- R&D is focused on key markets and high value therapeutic areas
- Partnerships are a key contributor to this business and we work hard to maintain our partner of choice status with global innovative pharma companies

Products: Broad portfolio of branded generics and in-licenced products – we are the partner of choice in the region

Customers: Pharmacies and hospitals across the region

Capabilities: Manufacturing facilities in seven countries, many of which are both locally approved, and US FDA and EMA-approved. 2,000 sales representatives and support staff across our 18 markets

Generics

Core Revenue

$672m

Key focus areas

- Differentiation – offer broad portfolio of differentiated products, including nasal sprays and respiratory
- Quality and operational efficiencies – world-class FDA-inspected facilities
- Pipeline – focus on adding complex and specialty products through R&D and partnerships

Products: Broad product portfolio encompassing oral solids and liquids and leader in US prescription nasal sprays

Customers: 90% of retail generics bought by three customer consortia

Capabilities: State of the art facility in Columbus Ohio, as well as US FDA-inspected facilities in Saudi Arabia and Jordan

Company information

Chief Executive Officer: Riad Mishlawi
Chief Financial Officer: Khalid Nabilsi
Hikma Pharmaceuticals PLC
1 New Burlington Place
London W1S 2HR

Contacts

Press: medainquiries@hikma.com
Investor Relations: UK-Investors@Hikma.com